NasdaqCM:JYNT

Stock Analysis Report

Executive Summary

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics.

Snowflake

Fundamentals

High growth potential with acceptable track record.

Share Price & News

How has Joint's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.9%

NasdaqCM:JYNT

1.3%

US Healthcare

1.2%

US Market


1 Year Return

116.4%

NasdaqCM:JYNT

-8.2%

US Healthcare

1.7%

US Market

JYNT outperformed the Healthcare industry which returned -8.2% over the past year.

JYNT outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

JYNTIndustryMarket
7 Day8.9%1.3%1.2%
30 Day7.8%-0.7%4.9%
90 Day13.9%0.01%3.7%
1 Year116.4%116.4%-6.8%-8.2%3.9%1.7%
3 Year710.9%710.9%30.1%24.9%47.2%37.7%
5 Yearn/a63.5%53.8%60.0%42.4%

Price Volatility Vs. Market

How volatile is Joint's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Joint undervalued based on future cash flows and its price relative to the stock market?

14%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Joint's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Joint's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Joint is overvalued based on earnings compared to the US Healthcare industry average.

Joint is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Joint is poor value based on expected growth next year.


Price Based on Value of Assets

Joint is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Joint expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

38.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Joint's revenue is expected to grow significantly at over 20% yearly.

Joint's earnings are expected to grow significantly at over 20% yearly.

Joint's revenue growth is expected to exceed the United States of America market average.

Joint's earnings growth is expected to exceed the United States of America market average.

Joint's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Joint will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Joint performed over the past 5 years?

16.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Joint's year on year earnings growth rate has been positive over the past 5 years.

Joint has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Joint has become profitable in the last year making it difficult to compare the US Healthcare industry average.


Return on Equity

Joint made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

Joint used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Joint has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Joint's financial position?


Financial Position Analysis

Joint is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Joint's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Joint's level of debt (36.6%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Joint's debt level has increased without past 5-year debt data.

Debt is well covered by operating cash flow (767.6%, greater than 20% of total debt).

Unable to confirm if the interest payments on Joint's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 12.4x debt.


Next Steps

Dividend

What is Joint's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Joint's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Joint's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Joint has not reported any payouts.

Unable to verify if Joint's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Joint has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Joint's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Peter Holt (60yo)

3.1yrs

Tenure

US$724,701

Compensation

Mr. Peter D. Holt has been Chief Executive Officer of The Joint Corp. since August 11, 2016 and has been its President since January 2017. Mr. Holt served as Interim Principal Financial Officer at The Join ...


CEO Compensation Analysis

Peter's remuneration is lower than average for companies of similar size in United States of America.

Peter's compensation has increased in line with Joint recently becoming profitable.


Management Age and Tenure

3.1yrs

Average Tenure

60yo

Average Age

The tenure for the Joint management team is about average.


Board Age and Tenure

2.2yrs

Average Tenure

59.5yo

Average Age

The average tenure for the Joint board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$64,32507 Jun 19
James Amos
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares4,000
Max PriceUS$16.08
SellUS$167,69124 May 19
Ronald DaVella
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,190
Max PriceUS$17.31
BuyUS$13,37102 Apr 19
Peter Holt
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares850
Max PriceUS$15.73
BuyUS$33,97121 Dec 18
James Amos
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$6.79
SellUS$22,86206 Dec 18
Ronald DaVella
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,000
Max PriceUS$7.62

Ownership Breakdown


Management Team

  • Craig Colmar (66yo)

    Secretary

    • Tenure: 9.5yrs
    • Compensation: US$75.27k
  • Peter Holt (60yo)

    CEO, President & Director

    • Tenure: 3.1yrs
    • Compensation: US$724.70k
  • Jason Greenwood

    Vice President of Marketing

    • Tenure: 0yrs
  • Steven Knauf

    Director of Chiropractic & Compliance

    • Tenure: 3.9yrs
  • Jorge Armenteros

    Vice President of Operations

    • Tenure: 2.7yrs
  • Jake Singleton (37yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
    • Compensation: US$1.35m
  • Eric Simon

    Vice President of Franchise Sales & Development

    • Tenure: 0yrs
  • David Glover

    Regional Developer for West Lake Hills

    • Tenure: 0yrs
  • Richard Matthews

    Director of Real Estate Research

    • Tenure: 0yrs
  • Amy Karroum

    Vice President of Human Resources

    • Tenure: 0yrs

Board Members

  • Glenn Krevlin (59yo)

    Director

    • Tenure: 0.3yrs
  • Jim Amos (73yo)

    Independent Director

    • Tenure: 4yrs
    • Compensation: US$85.00k
  • Suzanne Decker (57yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$80.00k
  • Matt Rubel (61yo)

    Lead Director

    • Tenure: 2.1yrs
    • Compensation: US$90.00k
  • Peter Holt (60yo)

    CEO, President & Director

    • Tenure: 3.1yrs
    • Compensation: US$724.70k
  • Biju Varkkey (54yo)

    Additional Independent Director

    • Tenure: 0.8yrs
  • Ron DaVella (62yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$88.75k
  • Abe Hong (47yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$54.36k

Company Information

The Joint Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: The Joint Corp.
  • Ticker: JYNT
  • Exchange: NasdaqCM
  • Founded: 2010
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$258.192m
  • Shares outstanding: 13.84m
  • Website: https://www.thejoint.com

Number of Employees


Location

  • The Joint Corp.
  • 16767 North Perimeter Drive
  • Suite 240
  • Scottsdale
  • Arizona
  • 85260
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
JYNTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2014
1JODB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct owner ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 01:03
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.